



PHARMACEUTICAL 2022










PHARMACEUTICAL 2022





The relative strengths and weaknesses of AYTU BIOPHARMA INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AYTU BIOPHARMA INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 132% points. The greatest weakness of AYTU BIOPHARMA INC is the variable Other Expenses, reducing the Economic Capital Ratio by 86% points.

The company's Economic Capital Ratio, given in the ranking table, is -43%, being 233% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	105,234
Cost of Goods Sold	36,432
Intangible Assets	151,266
Liabilities, Current	109,438
Liabilities, Non-Current	2,979
Other Assets	9,168
Other Compr. Net Income	0
Other Expenses	57,206
Other Liabilities	15,683
Other Net Income	840
Property and Equipment	0
Research and Development	5,623
Revenues	65,632
Selling, General and Administrative Expense	25,500

Output Variable	Value in 1000 USD
Assets	265,668
Liabilities	128,100
Expenses	124,761
Stockholders Equity	137,568
Net Income	-58,289
Comprehensive Net Income	-58,289
Economic Capital Ratio	-43%